n.c.a Lu-177

Home » n.c.a Lu-177

SHINE Technologies and ImaginAb Announce Lutetium-177 Clinical Supply Agreement

SHINE to supply n.c.a. Lu-177 for the clinical development of ImaginAb investigational radiopharmaceuticals

2022-09-08T09:10:15-05:00March 9, 2022|Healthier, News, News Releases, Therapeutics, 2022|

SHINE and Telix Pharmaceuticals Announce Lutetium-177 Clinical Supply Agreement

SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.

2022-02-09T20:42:58-06:00February 10, 2022|News, News Releases, 2022|

SHINE, EDH enter distribution agreement for SHINE’s non-carrier-added Lu-177

SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries

Go to Top